Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma

References

• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016 Apr 14;2(1):16018. doi: 10.1038/nrdp.2016.18
   PubMedGoogle Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA A Cancer J Clin. 2021 May;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Izumi N, Asahina Y, Noguchi O, et al. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer. 2001 Mar 1;91(5):949–956. doi: 10.1002/1097-0142(20010301)91:5<949:AID-CNCR1084>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Shimohira M, Ogino H, Kawai T, et al. Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma. Br J Radiol. 2011 Feb;84(998):184–187.
   PubMed Web of Science ®Google Scholar
• Ray CE, Brown AC, Green TJ, et al. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. Am J Roentgenol. 2015 Feb 01;204(2):440–447.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 Dec 06;362(9399):1907–1917.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022 Mar 01;76(3):681–693.
   PubMed Web of Science ®Google Scholar
• Tang H, Cao Y, Jian Y, et al. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: a review. Biosci Trends. 2022 May 17;16(2):130–141. doi: 10.5582/bst.2022.01019
   PubMed Web of Science ®Google Scholar
• Lai Q, Vitale A, Iesari S, et al. Intention‐to‐treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology. 2017;66(6):1910–1919. DOI:10.1002/hep.29342
   PubMed Web of Science ®Google Scholar
• Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in japan: jsh consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181–223. doi: 10.1159/000514174
   PubMed Web of Science ®Google Scholar
• Vogel A, Martinelli E, Vogel A, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021 Jun 01;32(6):801–805.
   PubMed Web of Science ®Google Scholar
• Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020 Mar 01;31(3):334–351.
   PubMed Web of Science ®Google Scholar
• Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update. Hepatol Res. 2019;49(10):1109–1113. doi: 10.1111/hepr.13411
   PubMed Web of Science ®Google Scholar
• Yoh T, Ishii T, Nishio T, et al. A conceptual classification of resectability for hepatocellular carcinoma. World J Surg. 2023 Mar 01;47(3):740–748.
   PubMed Web of Science ®Google Scholar
• Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study. Int J Surg. 2017 Aug;44:223–228.
   PubMed Web of Science ®Google Scholar
• Yoon SM, Ryoo B-Y, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018;4(5):661–669. doi: 10.1001/jamaoncol.2017.5847
   PubMed Web of Science ®Google Scholar
• He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019 Jul 1;5(7):953–960. doi: 10.1001/jamaoncol.2019.0250
   PubMed Web of Science ®Google Scholar
• Inoue Y, Hasegawa K, Ishizawa T, et al. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery. 2009 Jan;145(1):9–19. doi: 10.1016/j.surg.2008.09.005
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005 Apr;137(4):403–410.
   PubMed Web of Science ®Google Scholar
• Ban D, Shimada K, Yamamoto Y, et al. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointestinal Surg. 2009 Nov 01;13(11):1921–1928.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang G, Wang Y, et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? Ten years of experience. Oncology. 2016 Dec;21(12):1442–1449.
   Google Scholar
• Guiu B, Chevallier P, Assenat E, et al. Idarubicin-loaded beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial. Radiology. 2019;291(3):801–808. doi: 10.1148/radiol.2019182399
   PubMed Web of Science ®Google Scholar
• Brown DB, Nikolic B, Covey AM, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2012 Mar 01;23(3):287–294.
   PubMed Web of Science ®Google Scholar
• Liu J, Xu J, Zhang W, et al. Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma. Acad Radiol. 2020 May;27(5):704–709.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011 Oct 20;29(30):3960–3967. doi: 10.1200/JCO.2011.37.1021
   PubMed Web of Science ®Google Scholar
• Mathurin P, Raynard B, Dharancy S, et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther. 2003 May 15;17(10):1247–1261. doi: 10.1046/j.1365-2036.2003.01580.x
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60–69. doi: 10.1016/j.jhep.2018.02.008
   PubMed Web of Science ®Google Scholar
• Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006 Oct;17(10):1571–1593. doi: 10.1097/01.RVI.0000236744.34720.73
   PubMed Web of Science ®Google Scholar
• Baker T, Tabrizian P, Zendejas I, et al. Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. HPB (Oxford). 2022 Jul;24(7):1007–1018.
   PubMed Web of Science ®Google Scholar
• Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21(9):1142–1152. doi: 10.1002/lt.24169
   PubMed Web of Science ®Google Scholar
• Labgaa I, Tabrizian P, Titano J, et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. HPB. 2019;21(11):1497–1504. doi: 10.1016/j.hpb.2019.03.360
   PubMed Web of Science ®Google Scholar
• Lewandowski R, Kulik L, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920–1928. doi: 10.1111/j.1600-6143.2009.02695.x
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507. e2. doi: 10.1053/j.gastro.2010.10.049
   PubMed Web of Science ®Google Scholar
• Zhu LR, Li SS, Zheng WQ, et al. Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy. Front Immunol. 2023;14:1086078. doi: 10.3389/fimmu.2023.1086078
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi: 10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Adam R, Karam V, Cailliez V, et al. 2018 annual report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transplant Int. 2018;31(12):1293–1317. doi: 10.1111/tri.13358
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43. doi: 10.1016/S1470-2045(08)70284-5
   PubMed Web of Science ®Google Scholar
• Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long‐term outcome compared to tumors within Milan criteria. Hepatology. 2015;61(6):1968–1977. doi: 10.1002/hep.27752
   PubMed Web of Science ®Google Scholar
• Kardashian A, Florman SS, Haydel B, et al. Liver transplantation outcomes in a US multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria. Hepatology. 2020;72(6):2014–2028. doi: 10.1002/hep.31210
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020 Jul;21(7):947–956. doi: 10.1016/S1470-2045(20)30224-2
   PubMed Web of Science ®Google Scholar
• Yao FY, Fidelman N. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: where do we stand with tumor down‐staging? Hepatology. 2016;63(3):1014–1025. doi: 10.1002/hep.28139
   PubMed Web of Science ®Google Scholar
• Mehta N, Bhangui P, Yao FY, et al. Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104(6):1136–1142. doi: 10.1097/TP.0000000000003174
   PubMed Web of Science ®Google Scholar
• Minici R, Ammendola M, Manti F, et al. Safety and efficacy of degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE) in the downstaging of intermediate-stage Hepatocellular Carcinoma (hcc) in patients with a child-pugh score of 8-9. Front Pharmacol. 2021;12:634087. doi: 10.3389/fphar.2021.634087
   PubMed Web of Science ®Google Scholar
• Ho S-Y, Liu P-H, Hsu C-Y, et al. A new tumor burden score and albumin–bilirubin grade-based prognostic model for hepatocellular carcinoma. Cancers. 2022;14(3):649. doi: 10.3390/cancers14030649
   PubMed Web of Science ®Google Scholar
• Liao M, Zhu Z, Wang H, et al. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol. 2017;52(6–7):624–634. doi: 10.1080/00365521.2017.1292365
   PubMed Web of Science ®Google Scholar
• Alba E, Valls C, Dominguez J, et al. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. Am J Roentgenol. 2008;190(5):1341. doi: 10.2214/AJR.07.2972
   PubMed Web of Science ®Google Scholar
• Affonso BB, Galastri FL, da Motta Leal Filho JM, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol. 2019;25(37):5687. DOI:10.3748/wjg.v25.i37.5687
   PubMed Web of Science ®Google Scholar
• Walter F, Fuchs F, Gerum S, et al. HDR brachytherapy and SBRT as bridging therapy to liver transplantation in HCC patients: a single-center experience. Front Oncol. 2021;11:717792. doi: 10.3389/fonc.2021.717792
   PubMed Web of Science ®Google Scholar
• Seror O, N’Kontchou G, Nault JC, et al. Hepatocellular carcinoma within milan criteria: no-touch multibipolar radiofrequency ablation for treatment-long-term results. Radiology. 2016 Aug;280(2):611–621.
   PubMed Web of Science ®Google Scholar
• Qiao Z-Y, Zhang Z-J, Lv Z-C, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review. Front Immunol. 2021;12:653437. doi: 10.3389/fimmu.2021.653437
   PubMed Web of Science ®Google Scholar
• Schnickel GT, Fabbri K, Hosseini M, et al. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. Am J Transplant. 2022 Jun;22(6):1699–1704.
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant. 2021 May;21(5):1979–1980. doi: 10.1111/ajt.16448
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Abd El Aziz MA, Tartaglia N, et al. Microwave ablation versus radiofrequency ablation for treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Cancers (Basel). 2020 Dec 16;12(12):3796. doi: 10.3390/cancers12123796
   PubMed Web of Science ®Google Scholar
• Granito A, Facciorusso A, Sacco R, et al. TRANS-TACE: prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma. J Pers Med. 2021 Oct 17;11(10):1041. doi: 10.3390/jpm11101041
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi: 10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi: 10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi: 10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi: 10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021 Jul;22(7):977–990.
   PubMed Web of Science ®Google Scholar
• Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol. 2021 Sep 20;39(27):3002–3011. doi: 10.1200/JCO.21.00163
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Shi Q, Knox JJ, et al. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial. JAMA Oncol. 2019 Nov 1;5(11):1582–1588. doi: 10.1001/jamaoncol.2019.2792
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase iii, randomized clinical trial (LAUNCH). J Clin Oncol. 2023 Jan 1;41(1):117–127. doi: 10.1200/JCO.22.00392
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):77–90.
   PubMed Web of Science ®Google Scholar
• Qin S, Kudo M, Meyer T, et al. LBA36 Final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Ann Oncol. 2022 Sep 01;33:S1402–S1403.
   Web of Science ®Google Scholar
• Qin S, Chan LS, Gu S, et al. LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann Oncol. 2022 Sep 01;33:S1401–S1402.
   Web of Science ®Google Scholar
• Kelley RK, Rimassa L, Cheng A-L, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Aug 01;23(8):995–1008.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa Ghassan K, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evi. 2022 Jul 26;1(8):EVIDoa2100070.
   Google Scholar
• Finn RS, Kudo M, Merle P, et al. LBA34 Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022 Sep 01;33:S1401.
   Web of Science ®Google Scholar
• Shindoh J, Kawamura Y, Kobayashi Y, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol. 2021;28(12):7663–7672. doi: 10.1245/s10434-021-09974-0
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi: 10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Sun H-C, Zhu X-D, Huang C, et al. Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection. Am Soc Clin Oncol. 2020;38(15_suppl):e16690–e16690. doi: 10.1200/JCO.2020.38.15_suppl.e16690
   Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD, et al. Immune- related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018 Jan 11;378(2):158–168. doi: 10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Meserve J, Facciorusso A, Holmer AK, et al. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021 Feb;53(3):374–382.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Yau T, Cheng AL, et al. VP10-2021: cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial. Ann Oncol. 2022 Jan 01;33(1):114–116.
   Web of Science ®Google Scholar
• Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020 Jun;21(6):808–820.
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Ishigami M, Ito T, et al. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res. 2020;50(3):374–381. doi: 10.1111/hepr.13452
   PubMed Web of Science ®Google Scholar
• Boss D, Glen H, Beijnen J, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106(10):1598–1604. doi: 10.1038/bjc.2012.154
   PubMed Web of Science ®Google Scholar